Gufic BiosciencesBOM:509079 +1.91%75 Days Payable is 157.99 as of Mar. 2026, which is 3% above its 10-year median of 152.69. GuruFocus rates BOM:509079 with a GF Score™ of 75/100 and a GF Value™ of ₹408.46 (Fairly Valued). The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, Gufic Biosciences ranks better than 78.09% on this metric.
The historical rank and industry rank for Gufic Biosciences's Days Payable or its related term are showing as below:
BOM:509079'
s Days Payable Range Over the Past 10 Years
Min: 108.84 Med: 152.69 Max: 192.53
Current: 160.81
During the past 13 years, Gufic Biosciences's highest Days Payable was 192.53. The lowest was 108.84. And the median was 152.69.
BOM:509079's Days Payable is ranked better than 78.09% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs BOM:509079: 160.81
Gufic Biosciences's Days Payable
declined
from Mar. 2025 (161.55) to Mar. 2026 (157.99).
It may suggest that Gufic Biosciencesaccelerated paying its suppliers.
Gufic Biosciences Days Payable Related Terms
Gufic Biosciences Days Payable Historical Data
* Premium members only.
The historical data trend for Gufic Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gufic Biosciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Gufic Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Gufic Biosciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gufic Biosciences (BOM:509079) has a Days Payable of 157.99 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gufic Biosciences and its competitors. This is near median its historical median of 152.69. Over the past decade, Gufic Biosciences' Days Payable has ranged from 108.84 to 192.53. According to the industry distribution chart, Gufic Biosciences ranks #202 out of 922 companies in the Drug Manufacturers industry, placing it in the top 21.9%.
Is Gufic Biosciences' Days Payable too high?
Gufic Biosciences' current Days Payable of 157.99 is near median its 10-year median of 152.69. Over the past 10 years, this metric has ranged from a low of 108.84 to a high of 192.53. The Drug Manufacturers industry median Days Payable is 90.61. Gufic Biosciences' value of 157.99 is 74.4% above this industry median. Based on the distribution chart, Gufic Biosciences ranks #202 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gufic Biosciences has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gufic Biosciences ranks #202 out of 922 companies for Days Payable. This places Gufic Biosciences in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.61. Gufic Biosciences' value of 157.99 is 74.4% above this benchmark. Historically, Gufic Biosciences' own Days Payable has ranged from 108.84 to 192.53 over the past decade. While the company's 10-year median is 152.69 vs. the industry median of 90.61, Gufic Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gufic Biosciences's current Days Payable of 157.99 is 74.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gufic Biosciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gufic Biosciences's current Days Payable is 157.99, which is near median its own 10-year median of 152.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Fairly Valued. The stock's GF Value™ is ₹408.46, compared to a current price of ₹387.10 — trading 5.2% below its estimated fair value. The current Days Payable is 157.99, which is near median its 10-year median of 152.69 and 74.4% above the Drug Manufacturers industry median of 90.61. Gufic Biosciences' overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current Days Payable is 157.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gufic Biosciences (BOM:509079) Overvalued in 2026?
Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued.
The current stock price of ₹387.10 is trading 5.2% below its estimated GF Value™ of ₹408.46.
GuruFocus considers Gufic Biosciences to be Fairly Valued.
Key valuation signals for BOM:509079:
Days Payable: 157.99 (near median its 10-year median of 152.69)
GF Value™: ₹408.46 vs. price of ₹387.10 (5.2% below fair value)
Industry Position: 74.4% above the Drug Manufacturers median (#202 of 922)
No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
75GF Score
Get the complete analysis for BOM:509079
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:509079 has been successfully added to your 
